Correspondence 0001193805-22-001808 from Arcturus Therapeutics Holdings Inc. (ARCT) (CIK 0001768224) (ARCT)
Arcturus Therapeutics Holdings Inc. (ARCT) (CIK 0001768224)
Date: Dec. 30, 2022 · CIK: 0001768224 · Accession: 0001193805-22-001808
AI Filing Summary & Sentiment
File numbers found in text: 333-269003
Letter
Re: Arcturus Therapeutics Holdings Inc.
December 30, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Registration Statement on Form S-3
File No. 333-269003
Acceleration Request
Requested Date: December 30, 2022
Requested Time: 5:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Arcturus Therapeutics Holdings Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (Registration No. 333-269003) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement has been declared effective, please orally confirm that event with Jeffrey A. Baumel, Dentons US LLP, at (973) 912-7189 or Grant Levine, Dentons US LLP, at (212) 768-5384, outside counsel to the Company.
Sincerely,
Arcturus Therapeutics Holdings Inc.
Show Raw Text
CORRESP
1
filename1.htm
December 30, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re:
Arcturus Therapeutics Holdings Inc.
Registration Statement on Form S-3
File No. 333-269003
Acceleration Request
Requested Date: December 30, 2022
Requested Time: 5:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Arcturus Therapeutics Holdings Inc. (the “Company”)
hereby requests that the above-referenced Registration Statement on Form S-3 (Registration No. 333-269003) (the “Registration Statement”)
be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the
Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and
Exchange Commission. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the
Act. Once the Registration Statement has been declared effective, please orally confirm that event with Jeffrey A. Baumel, Dentons US
LLP, at (973) 912-7189 or Grant Levine, Dentons US LLP, at (212) 768-5384, outside counsel to the Company.
Sincerely,
Arcturus Therapeutics Holdings Inc.
/s/ Joseph E. Payne
Joseph E. Payne
Chief Executive Officer
cc:
Jeffrey A. Baumel, Dentons US LLP
Ilan Katz, Dentons US LLP
Grant Levine, Dentons US LLP